Effect of the VEGF-A–bevacizumab complex removal using immunoprecipitation on the concentrations of VEGF-A121, VEGF-A165, and VEGF-A. by Masashi Okawa (8951294)

Subjects:

VEGF-A121, VEGF-A165, and VEGF-A contents per unit platelets. by Masashi Okawa (8951294)

Subjects:

Blood concentrations of VEGF-A121, VEGF-A165, and VEGF-A pre- and post-bevacizumab administration. by Masashi Okawa (8951294)

Subjects:

Variations in slope utilization by a female red panda across different time periods and in comparison with their wild individuals. Different capital letters indicated significant d... by Yanshan Zhou (14131359)

Subjects:

Variations in altitude utilization by a female red panda across different time periods and in comparison with wild individuals. Different capital letters indicated significant diff... by Yanshan Zhou (14131359)

Subjects:

Variations in aspect utilization by a female red panda across different time periods and in comparison with wild individuals. Different capital letters indicated significant differ... by Yanshan Zhou (14131359)

Subjects:

Neutralization with additional bevacizumab to serum samples pre- and post-bevacizumab administration. by Masashi Okawa (8951294)

Subjects:

Changes in roughness of asphalt before and after aging and recycling. by Ying Fang (147352)

Ingenuity pathway analysis. by Wendy J. Bailey (14926392)

Subjects:

Effect of adding rhVEGF-A (-121 or -165) on the concentrations of VEGF-A121 and VEGF-A165 in plasma samples. by Masashi Okawa (8951294)

Subjects:

Surgery design. by Maria Nadinskaia (22662419)

Subjects:

Supporting information – data for plots. by Maria Nadinskaia (22662419)

Subjects:

Morphometric analysis of histological slides in sarcopenia modeling by portal vein ligation and pyloric vein ligation. by Maria Nadinskaia (22662419)

Subjects:

Effects of the observed significant angular changes at individual joints on the leading toe-obstacle clearance in healthy older adults during dual-task obstacle crossing (black sti... by Shiuan-Huei Lu (22430628)

Data Sheet 1_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx by David Qixiang Chen (8198265)

“…We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”

Data Sheet 2_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx by David Qixiang Chen (8198265)

“…We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”

Data Sheet 3_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx by David Qixiang Chen (8198265)

“…We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”

Changes in maximal strength within each group after treatment. by Sergio R. Thomaz (20308465)

Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i> by Razia Rashid Rahil (22772495)

“…(F-G) Representative western blots and summarized bar graph showed EVO significantly increased protein expression of SM22α and decreased RUNX2 in CER treated P_i-induced VSMCs. …”

Label-Free Quantitative Proteomic Analysis Reveals the Effects of Biogenic Silver Nanoparticles on Fusarium keratoplasticum and Their Therapeutic Potential in Galleria mellonella L... by Glaucia Rigotto-Caruso (22057974)

Subjects: